Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2012
- Total Asset Turnover since 2012
- Price to Book Value (P/BV) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Operating earnings1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2013 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of AbbVie Inc. Annual Report.
The Price to Operating Profit (P/OP) ratio for the period examined exhibits considerable fluctuation. Initially, the ratio increased significantly before stabilizing and then experiencing another period of volatility. A general observation is that the ratio tends to be higher when the share price increases relative to operating profit per share.
- Initial Increase (2013-2015)
- From 2013 to 2015, the P/OP ratio increased from 10.44 to 28.64. This rise was primarily driven by a substantial increase in share price from US$38.50 to US$61.30, while operating profit per share experienced a decrease from US$3.69 to US$2.14. This indicates that investor expectations grew faster than earnings during this period.
- Stabilization and Subsequent Rise (2016-2018)
- The ratio decreased to 11.61 in 2016, coinciding with a decline in share price. It then rose again, reaching 19.63 in 2018. This period saw both share price and operating profit per share increase, but the share price experienced a more dramatic increase. The share price rose from US$54.29 to US$118.60, while operating profit per share increased from US$4.68 to US$6.04.
- Fluctuation and Recent Trends (2019-2026)
- From 2019 through 2026, the P/OP ratio demonstrated significant volatility. It decreased to 18.35 in 2019, then decreased to 10.82 in 2020, before increasing to 16.32 in 2021. A further increase to 14.21 in 2022 was followed by a rise to 24.34 in 2023 and a substantial jump to 37.26 in 2024. The most recent value, in 2025, is 26.37. These fluctuations appear correlated with changes in both share price and operating profit per share, with the 2024 peak coinciding with the highest share price recorded in the period. The share price increased from US$79.41 to US$224.81 over this period, while operating profit per share fluctuated, ending at US$8.53.
Overall, the P/OP ratio suggests periods of investor optimism and pessimism, reflected in the relationship between share price and operating profit. The ratio’s recent increase warrants further investigation to determine if it is sustainable or indicative of potential overvaluation.
Comparison to Competitors
| AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | |||||||
| Feb 14, 2025 | |||||||
| Feb 20, 2024 | |||||||
| Feb 17, 2023 | |||||||
| Feb 18, 2022 | |||||||
| Feb 19, 2021 | |||||||
| Feb 21, 2020 | |||||||
| Feb 27, 2019 | |||||||
| Feb 16, 2018 | |||||||
| Feb 17, 2017 | |||||||
| Feb 19, 2016 | |||||||
| Feb 20, 2015 | |||||||
| Feb 21, 2014 | |||||||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).